Due to health issues, this site is no longer maintained and will be shut down shortly.

SE:MOLN Molecular Partners AG

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as is in Phase III clinical trials to treat diabetic macular edema diseases; and multi-VEGF/PDGF DARPin that is in preclinical studies for other ocular targets. The company is also developing MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc., F. Hoffmann-La Roche Ltd, and Janssen Biotech, Inc. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.This company has ADRs that trade in the U.S. as the symbol MOLN.

5.91 CHF
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Switzerland
Country of incorporation:  Switzerland
IPO date:  11/05/2014
Stock exchange:    Six Swiss Exchange
Exchange country:   Switzerland
Market cap:   227,896,192 CHF
Current dividend yield:   0.00%
Sedol:      BRJLB32

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy